VectivBio Holding AG (VECT)
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
VectivBio Holding is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need.
Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets.
Our product candidate, apraglutide, is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome, or SBS.
Apraglutide is currently being evaluated in a global Phase 3 clinical trial for the treatment of patients with SBS intestinal failure, or SBS-IF. We also plan to evaluate apraglutide’s therapeutic potential in additional rare GI conditions, such as graft versus host disease, that could benefit from GLP-2 activation.
|Dr. Luca Santarelli||Chief Executive Officer and Director|
|Dr. Claudia D’Augusta||Chief Financial Officer|
|Dr. Christian Meyer||Chief Development Officer|
|Kevin Harris||Chief Commercial Officer|
|Dr. Alain Bernard||Chief Technology Officer|
|Dr. Sarah Holland||Chief Business Officer|
|Dr. Thomas Woiwode||Chairman of the Board|
Latest SEC Filings
|Apr 9, 2021||424B4||Prospectus [Rule 424(b)(4)]|
|Apr 9, 2021||EFFECT||Notice of Effectiveness|
|Apr 8, 2021||CERT||Certification by an exchange approving securities for listing|
|Apr 7, 2021||F-1/A||Registration statement for certain foreign private issuers|
|Apr 6, 2021||8-A12B||Registration of securities [Section 12(b)]|
|Apr 5, 2021||F-1/A||Registration statement for certain foreign private issuers|
|Mar 19, 2021||F-1||Registration statement for certain foreign private issuers|
|Feb 5, 2021||DRS/A||Draft Registration Statement|
|Dec 22, 2020||DRS||Draft Registration Statement|
|View All SEC filings|